Tekla healthcare investorsHQH.US Overview
HQH Overall Performance
HQH AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
HQH Current Performance
-1.22%
Tekla healthcare investors
-0.20%
Avg of Sector
-0.43%
S&P500
HQH Key Information
HQH Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
HQH Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
HQH Profile
Tekla Healthcare Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. It was previously known as H&Q Healthcare Investors. Tekla Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.
Price of HQH
HQH FAQ
When is HQH's latest earnings report released?
The most recent financial report for Tekla healthcare investors (HQH) covers the period of 2024Q4 and was published on 2024/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HQH's short-term business performance and financial health. For the latest updates on HQH's earnings releases, visit this page regularly.
Where does HQH fall in the P/E River chart?
According to historical valuation range analysis, Tekla healthcare investors (HQH)'s current price-to-earnings (P/E) ratio is 2.52, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of HQH?
According to the latest financial report, Tekla healthcare investors (HQH) reported an Operating Profit of -189.15K with an Operating Margin of -3.46% this period, representing a growth of 81.5% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is HQH's revenue growth?
In the latest financial report, Tekla healthcare investors (HQH) announced revenue of 5.46M, with a Year-Over-Year growth rate of 17.15%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does HQH have?
At the end of the period, Tekla healthcare investors (HQH) held Total Cash and Cash Equivalents of 56, accounting for 0 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does HQH go with three margins increasing?
In the latest report, Tekla healthcare investors (HQH) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -3.46%%, and net margin of 1,560.21%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess HQH's profit trajectory and future growth potential.
Is HQH's EPS continuing to grow?
According to the past four quarterly reports, Tekla healthcare investors (HQH)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.59. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What are the PEG ratio and PE ratio of HQH?
The latest valuation data shows Tekla healthcare investors (HQH) has a Price-To-Earnings (PE) ratio of 2.52 and a Price/Earnings-To-Growth (PEG) ratio of -0.13. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.